Company intelligence / Profile preview

Enven

Boulder, Colorado, United Statesenven.com ↗

Ownership: Private
Employees: ~350
Development stage: Commercial

Overview

ENV‑294 is the first candidate discovered using Enveda’s AI-natural product platform. It has demonstrated robust efficacy and high safety margins in preclinical studies. The FDA cleared its IND application in late 2024, with dosing initiated in a Phase I trial by October 2024. A subsequent Phase Ib trial was launched by May 2025 focusing on atopic dermatitis patients.

Therapeutic areas: DermatologyImmunology
Modalities: Small molecule (natural product-derived)AI-powered drug discovery platform technologyMedicinal chemistry optimization of natural molecules
Industry: Biotech

Partnerships

Sanofi (investor)

Beyond the preview

Go deeper on Enven.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enven.

Explore the full profile